---
title: "Novo Nordisk outlines obesity and direct-to-consumer push, pledges five 'multi-blockbusters' by 20"
id: "stat-news-1-stat-with-new-strategy-novo-outlines-plans-for-obesity-direct-to-consumer-work"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-1-stat-with-new-strategy-novo-outlines-plans-for-obesity-direct-to-consumer-work"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/09/21/novo-nordisk-capital-markets-day-obesity-strategy/?utm_campaign=rss"
published_at: "2026-09-21T09:33:45.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Novo Nordisk outlines obesity and direct-to-consumer push, pledges five 'multi-blockbusters' by 20
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-1-stat-with-new-strategy-novo-outlines-plans-for-obesity-direct-to-consumer-work
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/09/21/novo-nordisk-capital-markets-day-obesity-strategy/?utm_campaign=rss)
- **Published At:** 2026-09-21T09:33:45.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Novo Nordisk used its capital markets day in London to present a strategy aimed at regaining growth and reducing reliance on its diabetes and obesity franchise. - CEO **Mike Doustdar** said the company expects to launch at least five **multi-blockbusters** by 2030 and to deliver revenue growth in line with other major pharmaceutical companies. - The plan includes expanding investments into disease areas beyond diabetes and obesity and being “more active within business development,” acknowledging investor concerns about concentration risk tied to **GLP-1** drugs. - Novo signaled intent to develop products that could be sold more like **consumer** goods, building on marketplace dynamics around its obesity treatments and direct-to-consumer opportunities. - Market reaction was muted: Novo shares fell about 5% during Doustdar’s opening remarks, suggesting investors sought more detailed execution plans and specifics. - The STAT News report is a STAT+ exclusive; the publicly available excerpt provides the key strategic claims but does not include detailed pipeline disclosures, named disease targets, product candidates, financial modeling, or timelines beyond the 2030 multi-blockbuster pledge. - Missing details in the source include the identities of the five programs, the specific new disease areas to receive increased investment, concrete direct-to-consumer tactics, estimated revenue or margin impacts, and timelines for the consumer-oriented product launches. - The article reflects the company’s messaging to investors but notes that additional specifics were not reported in the STAT+ excerpt, and the fuller STAT+ story requires subscription access.
## Clinical Analysis & Structured Key Points
Novo details new strategy in obesity, other disease areas Skip to Main Content STAT Plus Pharma With new strategy, Novo outlines plans for obesity, direct-to-consumer work The pioneer in diabetes and obesity has been under pressure to find new growth levers Manage alerts for this article Save this story for later Share this article Novo CEO Mike Doustdar Novo Nordisk By Andrew Joseph Sept. 21, 2026 Europe Correspondent Andrew Joseph [email protected] Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — Novo Nordisk on Monday sought to assure investors that it would regain its momentum in the coming years, outlining plans to expand its pipeline and find new products that it could sell more like consumer goods than traditional medicines, building off what’s occurring with its obesity treatments. At the company’s capital markets day, taking place here all day Monday, CEO Mike Doustdar said Novo would launch at least five multi-blockbusters by 2030 and deliver revenue growth on par with other major pharma firms. He presented a strategy that involved investing more in disease areas outside diabetes and obesity and said the company “will be more active within business development,” an acknowledgment of investors’ concerns that Novo was too reliant on its landmark GLP-1 drugs and needed to develop other products. Advertisement Novo shares dropped 5% during Doustdar’s opening remarks, a sign that investors wanted more specifics. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. Already have an account? Log in Individual plans Group plans Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In drug development , Obesity , Pharmaceuticals , STAT+ Submit a correction request Reprints Andrew Joseph Europe Correspondent Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Newsletter Understand how science, health policy, and medicine shape the world every day Please enter a valid email address. Sign Up Your data will be processed in accordance with our Privacy Policy and Terms of Service . You may opt out of receiving STAT communications at any time. Recommended Opinions+ Opinions+ September 21, 2026 STAT Plus: The NIH budget should be $100 billion per year Politics Politics September 21, 2026 STAT Plus: Can RFK Jr. help GOP win the midterms? Iowa is a test Advertisement STATus Report STATus Report September 21, 2026 Why is trust in science important? Trust in Science Trust in Science September 21, 2026 Skeptical about modern medicine? I know the feeling — and want to listen Health Health September 21, 2026 Addiction clinics see rising cases of kratom and 7-OH withdrawal Subscriber Picks
## Related Clinical Research

- [Trump Announces GENEROUS Medicaid Drug-Discount Model; 40 States Reportedly Signed So Far](https://medichelpline.com/clinical-feed/stat-news-0-stat-trump-touts-pharma-deals-to-offer-cheaper-drugs-to-state-medicaid-programs.md)
- [Pharmalot job moves: IN8bio hires Oxana Polyakova as senior VP, R&D](https://medichelpline.com/clinical-feed/stat-news-1-stat-up-and-down-the-ladder-the-latest-comings-and-goings.md)
- [Real-world uptake of SGLT2 inhibitors in heart failure across ejection fraction: Swedish registry](https://medichelpline.com/clinical-feed/pubmed-42001463.md) (DOI: 10.1093/ehjqcco/qcag063)
- [SGLT2 inhibitors and outcomes across cardio‑reno‑metabolic disease by BMI: a randomized trials met](https://medichelpline.com/clinical-feed/pubmed-41948998.md) (DOI: 10.1093/ehjqcco/qcag061)
- [Obesity-associated inflammation and cancer: mechanisms linking adipose immune changes to tumor risk](https://medichelpline.com/clinical-feed/frontiers-in-immunology-6-obesity-associated-inflammation-and-cancer-molecular-mechanisms-evidence-gaps.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.